Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | IGF1R | P08069 | 1/20 | 0.50 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.47 |
| ▸ | HTR3B | O95264 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.47 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9127398 | 0.93 | IGF1R (0.53) | TAAR1ALOX15IGF1RHTR3EHTR3B | |
| SCHEMBL6067810 | 0.91 | IGF1R (0.52) | TAAR1ALOX15IGF1RHTR3EHTR3B | |
| SCHEMBL11400125 | 0.91 | IGF1R (0.52) | TAAR1ALOX15IGF1RHTR3EHTR3B | |
| SCHEMBL2657239 | 0.87 | TAAR1 (0.59) | TAAR1ALOX15IGF1RHTR3EHTR3B | |
| Glutaral SCHEMBL9719285 | 0.84 | IGF1R (0.43) | TAAR1ALOX15IGF1RHTR3EHTR3B | |
| SCHEMBL18050371 | 0.84 | TAAR1 (0.62) | TAAR1ALOX15IGF1RHTR3EHTR3B | |
| SCHEMBL10365734 | 0.84 | IGF1R (0.64) | TAAR1ALOX15IGF1RHTR3EHTR3B | |
| SCHEMBL28966782 | 0.81 | IGF1R (0.61) | TAAR1ALOX15IGF1RHTR3EHTR3B | |
| SCHEMBL1115439 | 0.81 | IGF1R (0.61) | TAAR1ALOX15IGF1RHTR3EHTR3B | |
| SCHEMBL1044301 | 0.80 | TAAR1 (0.52) | TAAR1ALOX15IGF1RHTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112979693-A | Alkyl trimethyl tin compounds, and preparation method and application thereof | 天津师范大学 | 2021-06-18 | — | — | CN | claimed |
| CN-112979693-B | Alkyl trimethyl tin compounds, and preparation method and application thereof | 天津师范大学 | 2023-03-28 | — | — | CN | disclosed |
| CN-112979693-A | Alkyl trimethyl tin compounds, and preparation method and application thereof | 天津师范大学 | 2021-06-18 | — | — | CN | disclosed |
| WO-2017082924-A1 | PEPTIDE AND PEPTIDE MIMETIC BINDING ANTAGONISTS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2017-05-18 | — | — | WO | disclosed |
| US-8101650-B2 | Method for treating a immunology-related disease | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-24 | — | — | US | disclosed |
| US-8067396-B2 | Amino alcohol compounds or phosphonic acid derivatives thereof | SANKYO COMPANY, LIMITED (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20100311798-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | HOFFMANN-LA ROCHE, INC. | 2010-12-09 | — | — | US | disclosed |
| WO-2010139707-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-09 | — | — | WO | disclosed |
| US-20100035842-A1 | Amino alcohol compounds or phosphonic acid derivatives thereof | SANKYO COMPANY, LIMITED (JP) | 2010-02-11 | — | — | US | disclosed |
| US-20090326038-A1 | Method for treating a immunology-related disease | SANKYO COMPANY, LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| US-5861428-A | ALLEVIATION OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, SEPTIC ARTHRITIS, PERIODONTAL DISEASE, CORNEAL ULCERATION, PROTEINURIA, ANEURYSMAL AORTIC DISEASE, DYSTROPHOBIC EPIDERMOLYSIS BULLOSA, INFLAMMATION, OSTEOPENIAS, TEMPERO | BAYER CORPORATION (US) | 1999-01-19 | — | — | US | disclosed |
| US-5859047-A | ANTIARTHRITIC AGENTS, NERVOUS SYSTEM DISORDERS | BAYER CORPORATION (US) | 1999-01-12 | — | — | US | disclosed |
| US-5854277-A | Thiophenebutanoic acid derivatives as matrix metalloprotease inhibitors | BAYER CORPORATION (US) | 1998-12-29 | — | — | US | disclosed |
| US-5789434-A | ACID, ESTER OR AMIDE DERIVATIVES AS ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS AND REDUCTION OF CARTILAGE DETERIORATION | BAYER CORPORATION (US) | 1998-08-04 | — | — | US | disclosed |
| CN-1163604-A | Substituted 4-diarylbutanoic or 5-diarylpentanoic acids and derivatives thereof as matrix metalloproteinase inhibitors | BAYER AG (US) | 1997-10-29 | — | — | CN | disclosed |
| EP-0790974-A1 | SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS | Bayer Corporation (US) | 1997-08-27 | — | — | EP | disclosed |
| WO-1996015096-A1 | SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS | BAYER CORPORATION (US) | 1996-05-23 | — | — | WO | disclosed |
| US-4987132-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1991-01-22 | — | — | US | disclosed |
| EP-0279681-A2 | Saturated heterocyclic carboxamide derivatives | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1988-08-24 | — | — | EP | disclosed |
| US-4004016-A | ANTIINFLAMMATORY | E. R. SQUIBB & SONS, INC. (US) | 1977-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311798-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | TAAR1, TAAR5, NPY2R | TAAR1 1/4885ALOX15 1263/4885IGF1R 890/4885 |
| US-20090326038-A1 | Method for treating a immunology-related disease | C3AR1, HRH3, HRH2 | TAAR1 309/4885ALOX15 166/4885IGF1R 1149/4885 |
| US-20100035842-A1 | Amino alcohol compounds or phosphonic acid derivatives thereof | PHOSPHO1, ADH1C, ADH1A | TAAR1 12/4885ALOX15 617/4885IGF1R 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.